Drugs / ONO-5334
last change Feb 2014 re-read 2 minutes ago

ONO-5334

targets CTSK via inhibition

Developed for
osteoporosis
Investigated by
Ono Pharmaceutical Co., Ltd.

Trials 1 · a red edge is where a trial was stopped

20112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT01384188 Jun → Dec 2011 Ono Pharmaceutical Co., Ltd. Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00532337 Comparator Oct 2007 → Jul 2010 osteoporosis Ono Pharma USA Inc Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as ONO-5334 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01384188
1

NCT00532337

Action Inhibit “Cathepsin K inhibition with ONO-5334 resulted in decreases in most resorption markers over 2 years” PMID 23873670 Feb 2014
1

“Cathepsin K inhibitor” CHEMBL4802176

Target CTSK “Cathepsin K inhibitor” CHEMBL4802176